Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 4/20 | 0.41 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.41 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.41 |
| ▸ | HCAR2 | Q8TDS4 | 6/20 | 0.41 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.37 |
| ▸ | KDM5A | P29375 | 3/20 | 0.37 |
| ▸ | KDM4C | Q9H3R0 | 3/20 | 0.37 |
| ▸ | KDM5B | Q9UGL1 | 3/20 | 0.37 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.37 |
| ▸ | AGBL2 | Q5U5Z8 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | KDM4A | O75164 | 1/20 | 0.36 |
| ▸ | GRM5 | P41594 | 1/20 | 0.36 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.36 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15519258 | 0.86 | HCAR2 (0.49) | ARHCRTR1HCRTR2HCAR2GRIA1 | |
| SCHEMBL31586867 | 0.84 | L3MBTL1 (0.41) | ARHCRTR1HCRTR2HCAR2GRIA1 | |
| SCHEMBL15519617 | 0.84 | AR (0.45) | ARHCRTR1HCRTR2HCAR2GRIA1 | |
| SCHEMBL13933900 | 0.83 | HCRTR1 (0.40) | ARHCRTR1HCRTR2HCAR2GRIA1 | |
| SCHEMBL15519920 | 0.82 | TYK2 (0.44) | ARHCRTR1HCRTR2HCAR2 | |
| SCHEMBL13933901 | 0.79 | GRIA1 (0.37) | ARHCRTR1HCRTR2HCAR2GRIA1 | |
| SCHEMBL18611527 | 0.79 | GRIA1 (0.40) | ARHCRTR1HCRTR2HCAR2GRIA1 | |
| SCHEMBL31587275 | 0.79 | KMT2A (0.55) | ARLMNA | |
| SCHEMBL16649082 | 0.78 | GRIA1 (0.38) | ARHCRTR1HCRTR2HCAR2GRIA1 | |
| SCHEMBL15522023 | 0.78 | HCAR2 (0.41) | ARHCRTR1HCRTR2HCAR2GRIA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025104236-A1 | PYRAZOLE COMPOUNDS AS CULLIN RING UBIQUITIN LIGASE COMPOUNDS | PROXYGEN GMBH (AT) | 2025-05-22 | — | — | WO | disclosed |
| US-20140081025-A1 | HETEROAROMATIC RING DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2014-03-20 | — | — | US | disclosed |
| EP-2708537-A1 | HETEROAROMATIC RING DERIVATIVE | Taisho Pharmaceutical Co., Ltd. (JP) | 2014-03-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140081025-A1 | HETEROAROMATIC RING DERIVATIVE | HCRTR2, HCRTR1, HTT | AR 903/4885HCRTR1 2/4885HCRTR2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.